(Q28218447)

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

1 reference

C J Clements

1

0 references

E Griffiths

series ordinal

2

0 references

C.J. Clements

series ordinal

1

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

E. Griffiths

series ordinal

2

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

language of work or name

English

0 references

publication date

31 May 2002

0 references

May 2002

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

volume

20 Suppl 3

0 references

20

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

page(s)

S24-33

0 references

S24-S33

1 reference

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953.

23 March 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Combined tetanus-diphtheria immunization of adults: use of small doses of diphtheria toxoid

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Diphtheria: changing patterns in the developing world and the industrialized world

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Neurologic complications of immunizations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Adverse reactions after injection of adsorbed diphtheria-pertussis-tetanus (DPT) vaccine are not due only to pertussis organisms or pertussis components in the vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Family history of convulsions and use of pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Overview of clinical studies with hepatitis B vaccine made by recombinant DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Immunogenicity and safety of low doses of recombinant yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Multicenter Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

Anaphylaxis after hepatitis B vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900168-8

1 reference

7 January 2021

10.1016/S0264-410X(02)00168-8

Identifiers

DOI

2 references

https://doi.org/10.1016%2FS0264-410X%2802%2900168-8

23 March 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1147841

OpenCitations bibliographic resource ID

1147841

1 reference